ClinConnect ClinConnect Logo
Search / Trial NCT01709864

NVA237 Versus Placebo 12-week Efficacy Study

Launched by NOVARTIS PHARMACEUTICALS · Oct 16, 2012

Trial Information

Current as of May 04, 2025

Completed

Keywords

Anticholinergic Antimuscarinic Chronic Obstructive Airway Disease Chronic Obstructive Lung Disease Chronic Obstructive Pulmonary Disease Copd Lama Lung Disease Lung Diseases, Obstructive Lung Function Muscarinic Receptor Antagonist Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. Patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011).
  • 2. Patients with Forced Expiratory Volume in one second (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/ Forced Vital Capacity (FVC) \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.
  • 3. Current or ex-smokers with at least 10 cigarette pack years smoking history.
  • Exclusion criteria:
  • 1. Patients with a history of long QT syndrome, with a prolonged QTc measured during screening, or patients who have a clinically significant ECG abnormality at screening.
  • 2. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • 3. Pregnant or nursing (lactating) women. Women of childbearing potential unless using an effective method of contraception.
  • 4. Patients who in the judgment of the investigator, would be at potential risk if enrolled into the study.
  • 5. Patients who have a clinically significant concomitant disease at screening, including but not limited to clinically significant laboratory abnormalities, clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with uncontrolled diabetes, which could interfere with the assessment of the efficacy and safety of the study treatment.
  • 6. Patients with a body mass index (BMI) of more than 40 kg/m2.
  • 7. Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, or sympathomimetic amines.
  • 8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or patients with a high blood eosinophil count during screening.
  • Other protocol-defined inclusion/exclusion criteria may apply.

About Novartis Pharmaceuticals

Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.

Locations

Los Angeles, California, United States

Fountain Valley, California, United States

Fullerton, California, United States

Miami, Florida, United States

Spartanburg, South Carolina, United States

Arlington, Texas, United States

Winter Park, Florida, United States

Raleigh, North Carolina, United States

Waco, Texas, United States

Pompano Beach, Florida, United States

Tamarac, Florida, United States

Charlotte, North Carolina, United States

Union, South Carolina, United States

Tucson, Arizona, United States

Columbia, South Carolina, United States

Simpsonville, South Carolina, United States

Jasper, Alabama, United States

Riverside, California, United States

Pensacola, Florida, United States

South Miami, Florida, United States

Tampa, Florida, United States

Gaffney, South Carolina, United States

Greenville, South Carolina, United States

Port Orange, Florida, United States

Homewood, Alabama, United States

Hialeah, Florida, United States

Clearwater, Florida, United States

Beaumont, Texas, United States

Dallas, Texas, United States

Shelby, North Carolina, United States

Easley, South Carolina, United States

Sarasota, Florida, United States

Seneca, South Carolina, United States

Charleston, South Carolina, United States

Defuniak Springs, Florida, United States

Ninety Six, South Carolina, United States

Fort Lauderdale, Florida, United States

Brandon, Florida, United States

*See Various Dept.'S*, Arizona, United States

San Diego, California, United States

Edgewater, Florida, United States

Summerfield, Florida, United States

Las Vegas, Nevada, United States

Rock Hll, South Carolina, United States

Amarillo, Texas, United States

Huntsville, Texas, United States

Patients applied

0 patients applied

Trial Officials

Novartis Pharmaceuticals

Study Director

Novartis Pharmaceuticals

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials